
Patent Claims

1. Compound of the formula



(I),


in which

R^1 represents chlorine, trifluoromethoxy, methyl, ethyl, n-propyl, methoxy, methoxymethyl or ethoxymethyl,


R^2 represents hydrogen or methyl,

and

R^3 represents a group of the formula



or



,

where

* is the point of attachment to the oxopyridine ring,

n represents the number 1, 2, 3 or 4,

m represents the number 1 or 2,

R^4 represents hydrogen, methyl, ethyl, cyclopropyl, cyclobutyl, 2-hydroxyeth-1-yl, 3-hydroxyprop-1-yl, 2-methoxyeth-1-yl, 3-methoxyprop-1-yl, 4-hydroxycyclohex-1-yl, tetrahydrofuran-2-ylmethyl or 1,4-dioxan-2-ylmethyl,

R^5 represents hydrogen, methyl or ethyl,

or

R^4 and R^5 together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl ring, a 2-methoxymethylpyrrolidin-1-yl ring, a morpholin-4-yl ring, a 1,1-dioxothiomorpholin-4-yl ring, a 1,4-oxazepan-4-yl ring, a 4-methylpiperazin-1-yl or a 4-hydroxypiperidin-1-yl ring,

R^6 represents hydrogen, methyl, ethyl, cyclopropyl, cyclobutyl, 2-hydroxyeth-1-yl, 3-hydroxyprop-1-yl, 2-methoxyeth-1-yl, 3-methoxyprop-1-yl, 4-hydroxycyclohex-1-yl, tetrahydrofuran-2-ylmethyl or 1,4-dioxan-2-ylmethyl,

R^7 represents hydrogen, methyl or ethyl,

R^6 and R^7 together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl ring, a 2-methoxymethylpyrrolidin-1-yl ring, a morpholin-4-yl ring, a 1,1-dioxothiomorpholin-4-yl ring, a 1,4-oxazepan-4-yl ring, a 4-methylpiperazin-1-yl or a 4-hydroxypiperidin-1-yl ring,

or one of its salts, its solvates or the solvates of its salts.


2. Compound according to Claim 1, characterized in that

R^1 represents chlorine, trifluoromethoxy, methyl, ethyl, n-propyl, methoxy or methoxymethyl,

R^2 represents hydrogen or methyl,

and

R^3 represents a group of the formula



,

where

* is the point of attachment to the oxopyridine ring,

n is the number 1, 2 or 3,

m represents the number 1 or 2,

R^4 represents hydrogen, methyl, ethyl, cyclopropyl, cyclobutyl, 2-hydroxyeth-1-yl, 3-hydroxyprop-1-yl, 2-methoxyeth-1-yl, 3-methoxyprop-1-yl, 4-hydroxycyclohex-1-yl, tetrahydrofuran-2-ylmethyl or 1,4-dioxan-2-ylmethyl,

R^5 represents hydrogen, methyl or ethyl,

or

R^4 and R^5 together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl ring, a 2-methoxymethylpyrrolidin-1-yl ring, a morpholin-4-yl ring, a 1,1-dioxothiomorpholin-4-yl ring, a 1,4-oxazepan-4-yl ring, a 4-methylpiperazin-1-yl or a 4-hydroxypiperidin-1-yl ring,

R^6 represents hydrogen, methyl, ethyl, cyclopropyl, cyclobutyl, 2-hydroxyeth-1-yl, 3-hydroxyprop-1-yl, 2-methoxyeth-1-yl, 3-methoxyprop-1-yl, 4-hydroxycyclohex-1-yl, tetrahydrofuran-2-ylmethyl or 1,4-dioxan-2-ylmethyl,

R^7 represents hydrogen, methyl or ethyl,

R^6 and R^7 together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl ring, a 2-methoxymethylpyrrolidin-1-yl ring, a morpholin-4-yl ring, a 1,1-dioxothiomorpholin-4-yl ring, a 1,4-oxazepan-4-yl ring, a 4-methylpiperazin-1-yl or a 4-hydroxypiperidin-1-yl ring,

or one of its salts, its solvates or the solvates of its salts.


3. Compound according to Claim 1 or 2, characterized in that

R^1 represents methyl, ethyl, n-propyl, methoxy or methoxymethyl,

R^2 represents hydrogen or methyl,

and

R^3 represents a group of the formula



where

* is the point of attachment to the oxopyridine ring,

n is the number 1, 2 or 3,

m represents the number 1 or 2,

R^4 represents hydrogen, methyl, ethyl, cyclopropyl, cyclobutyl, 2-hydroxyeth-1-yl, 3-hydroxyprop-1-yl, 2-methoxyeth-1-yl, 3-methoxyprop-1-yl, 4-hydroxycyclohex-1-yl, tetrahydrofuran-2-ylmethyl or 1,4-dioxan-2-ylmethyl,

R^5 represents hydrogen, methyl or ethyl,

R^6 represents hydrogen, methyl, ethyl, cyclopropyl, cyclobutyl, 2-hydroxyeth-1-yl, 3-hydroxyprop-1-yl, 2-methoxyeth-1-yl, 3-methoxyprop-1-yl, 4-hydroxycyclohex-1-yl, tetrahydrofuran-2-ylmethyl or 1,4-dioxan-2-ylmethyl,

R^7 represents hydrogen, methyl or ethyl,

or one of its salts, its solvates or the solvates of its salts.

4. Compound according to any of Claims 1 to 3, characterized in that

R^1 represents methyl or methoxy,

R^2 represents hydrogen,


or

R^1 represents methyl,

R^2 represents methyl,

and

R^3 represents a group of the formula



where

* is the point of attachment to the oxopyridine ring,

n represents the number 2,

m represents the number 1,

R^4 represents 2-hydroxyeth-1-yl or 4-hydroxycyclohex-1-yl,

R^5 represents hydrogen,

R^6 represents 2-hydroxyeth-1-yl or 4-hydroxycyclohex-1-yl,

R^7 represents hydrogen,

or one of its salts, its solvates or the solvates of its salts.

5. Compound according to any of Claims 1 to 3, characterized in that

R^1 represents methoxymethyl,

R^2 represents hydrogen,


or

R^1 represents methyl,

R^2 represents methyl,

and

R^3 represents a group of the formula



,

where

* is the point of attachment to the oxopyridine ring,

n represents the number 2,

R^4 represents 2-hydroxyeth-1-yl or 4-hydroxycyclohex-1-yl,

R^5 represents hydrogen,

or one of its salts, its solvates or the solvates of its salts.

6. Compound according to any of Claims 1 to 4, characterized in that

R^1 represents methyl,

R^2 represents hydrogen,


or

R^1 represents methyl,

R^2 represents methyl,

and

R^3 represents a group of the formula



,

where

* is the point of attachment to the oxopyridine ring,

m represents the number 1,


R^6 represents 2-hydroxyeth-1-yl or 4-hydroxycyclohex-1-yl,

R^7 represents hydrogen,

or one of its salts, its solvates or the solvates of its salts.

7. Process for preparing a compound of the formula (I) or one or its salts, its solvates or the solvates of its salts according to Claim 1, characterized in that

[A] a compound of the formula




(II),

in which n, R^1 and R^2 have the meaning given in Claim 1, and

X represents hydroxyl or bromine,


is reacted with a compound of the formula



(III)

in which R^4 and R^5 have the meaning given in Claim 1,

to give a compound of the formula




(Ia)

in which n, R^1, R^2, R^4 and R^5 have the meaning given in Claim 1,

or

[B] a compound of the formula




(IV)

in which m, R^1 and R^2 have the meaning given in Claim 1, and

Y represents hydroxyl or chlorine,


is reacted with a compound of the formula



(V)

in which R^6 and R^7 have the meaning given in Claim 1,

to give a compound of the formula



(Ib)

in which m, R^1, R^2, R^6 and R^7 have the meaning given in Claim 1.

8. Compound according to any of Claims 1 to 6 for the treatment and/or prophylaxis of diseases.

9. Use of a compound according to any of Claims 1 to 6 for preparing a medicament for the treatment and/or prophylaxis of diseases.

10. Use of a compound according to any of Claims 1 to 6 for preparing a medicament for the treatment and/or prophylaxis of thromboembolic disorders.

11. Use of a compound according to any of Claims 1 to 6 for preventing blood coagulation in vitro.

12. Medicament, comprising a compound according to any of Claims 1 to 6 in combination with an inert nontoxic pharmaceutically acceptable auxiliary.

13. Medicament comprising a compound according to any of Claims 1 to 6 in combination with a further active compound.

14. Medicament according to Claim 12 or 13 for the treatment and/or prophylaxis of thromboembolic disorders.

15. Method for preventing blood coagulation in vitro, characterized in that an anticoagulatory effective amount of a compound according to any of Claims 1 to 6 is added.


16. Use of a compound according to any of Claims 1 to 6 for preparing a medicament for the treatment and/or prophylaxis of pulmonary hypertension.

17. Use of a compound according to any of Claims 1 to 6 for preparing a medicament for the treatment and/or prophylaxis of sepsis, systemic inflammatory syndrome (SIRS), septic organ dysfunction, septic organ failure and multiorgan failure, acute respiratory distress syndrome (ARDS), acute lung injury (ALI), septic shock and/or DIC ("disseminated intravascular coagulation").

18. Compound as defined in any of Claims 1 to 6 for use in a method for the treatment and/or prophylaxis of thromboembolic disorders.

CLAIMS

1. A compound of the formula



(I),


in which

R^1 represents chlorine, trifluoromethoxy, methyl, ethyl, n-propyl, methoxy, methoxymethyl or ethoxymethyl,

R^2 represents hydrogen or methyl,

and

R^3 represents a group of the formula



,

where

* is the point of attachment to the oxopyridine ring,

n represents the number 1, 2, 3 or 4,

m represents the number 1 or 2,

R^4 represents, methyl, ethyl, cyclopropyl, cyclobutyl, 2-hydroxyeth-1-yl, 3-hydroxyprop-1-yl, 2-methoxyeth-1-yl, 3-methoxyprop-1-yl, 4-hydroxycyclohex-1-yl, tetrahydrofuran-2-ylmethyl or 1,4-dioxan-2-

ylmethyl,

R^5 represents hydrogen, methyl or ethyl,

or

R^4 and R^5 together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl ring, a 2-methoxymethylpyrrolidin-1-yl ring, a morpholin-4-yl ring, a 1,1-dioxothiomorpholin-4-yl ring, a 1,4-oxazepan-4-yl ring, a 4-methylpiperazin-1-yl or a 4-hydroxypiperidin-1-yl ring,

R^6 represents hydrogen, methyl, ethyl, cyclopropyl, cyclobutyl, 2-hydroxyeth-1-yl, 3-hydroxyprop-1-yl, 2-methoxyeth-1-yl, 3-methoxyprop-1-yl, 4-hydroxycyclohex-1-yl, tetrahydrofuran-2-ylmethyl or 1,4-dioxan-2-ylmethyl,

R^7 represents hydrogen, methyl or ethyl,

R^6 and R^7 together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl ring, a 2-methoxymethylpyrrolidin-1-yl ring, a morpholin-4-yl ring, a 1,1-dioxothiomorpholin-4-yl ring, a 1,4-oxazepan-4-yl ring, a 4-methylpiperazin-1-yl or a 4-hydroxypiperidin-1-yl ring,

or one of its salt.


2. A compound according to Claim 1, wherein

R^1 represents chlorine, trifluoromethoxy, methyl, ethyl, n-propyl, methoxy or methoxymethyl,

R^2 represents hydrogen or methyl,

and

R^3 represents a group of the formula



where

* is the point of attachment to the oxopyridine ring,

n is the number 1, 2 or 3,

m represents the number 1 or 2,

R^4 represents, methyl, ethyl, cyclopropyl, cyclobutyl, 2-hydroxyeth-1-yl, 3-hydroxyprop-1-yl, 2-methoxyeth-1-yl, 3-methoxyprop-1-yl, 4-hydroxycyclohex-1-yl, tetrahydrofuran-2-ylmethyl or 1,4-dioxan-2-ylmethyl,

R^5 represents hydrogen, methyl or ethyl,

or

R^4 and R^5 together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl ring, a 2-methoxymethylpyrrolidin-1-yl ring, a morpholin-4-yl ring, a 1,1-dioxothiomorpholin-4-yl ring, a 1,4-oxazepan-4-yl ring, a 4-methylpiperazin-1-yl or a 4-hydroxypiperidin-1-yl ring,

R^6 represents hydrogen, methyl, ethyl, cyclopropyl, cyclobutyl, 2-hydroxyeth-1-yl, 3-hydroxyprop-1-yl, 2-methoxyeth-1-yl, 3-methoxyprop-1-yl, 4-hydroxycyclohex-1-yl, tetrahydrofuran-2-ylmethyl or 1,4-dioxan-2-ylmethyl,

R^7 represents hydrogen, methyl or ethyl,

R^6 and R^7 together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl ring, a 2-methoxymethylpyrrolidin-1-yl ring, a morpholin-4-yl ring, a 1,1-dioxothiomorpholin-4-yl ring, a 1,4-oxazepan-

4-yl ring, a 4-methylpiperazin-1-yl or a 4-hydroxypiperidin-1-yl ring,

or one of its salts.


3. A compound according to Claim 1, wherein

R^1 represents methyl, ethyl, n-propyl, methoxy or methoxymethyl,

R^2 represents hydrogen or methyl,

and

R^3 represents a group of the formula



,

where

* is the point of attachment to the oxopyridine ring,

n is the number 1, 2 or 3,

m represents the number 1 or 2,

R^4 represents, methyl, ethyl, cyclopropyl, cyclobutyl, 2-hydroxyeth-1-yl, 3-hydroxyprop-1-yl, 2-methoxyeth-1-yl, 3-methoxyprop-1-yl, 4-hydroxycyclohex-1-yl, tetrahydrofuran-2-ylmethyl or 1,4-dioxan-2-ylmethyl,

R^5 represents hydrogen, methyl or ethyl,

R^6 represents hydrogen, methyl, ethyl, cyclopropyl, cyclobutyl, 2-hydroxyeth-1-yl, 3-hydroxyprop-1-yl, 2-methoxyeth-1-yl, 3-methoxyprop-1-yl, 4-hydroxycyclohex-1-yl, tetrahydrofuran-2-ylmethyl or 1,4-dioxan-2-ylmethyl,

R^7 represents hydrogen, methyl or ethyl,

or one of its salts.

4. A compound according to Claim 1, wherein

R^1 represents methyl or methoxy,

R^2 represents hydrogen,


or

R^1 represents methyl,

R^2 represents methyl,

and

R^3 represents a group of the formula



,

where

* is the point of attachment to the oxopyridine ring,

n represents the number 2,

m represents the number 1,

R^4 represents 2-hydroxyeth-1-yl or 4-hydroxycyclohex-1-yl,

R^5 represents hydrogen,

R^6 represents 2-hydroxyeth-1-yl or 4-hydroxycyclohex-1-yl,

R^7 represents hydrogen,

or one of its salts.

5. A compound according to Claim 1, wherein

R^1 represents methoxymethyl,

R^2 represents hydrogen,


or

R^1 represents methyl,

R^2 represents methyl,

and

R^3 represents a group of the formula



,

where

* is the point of attachment to the oxopyridine ring,

n represents the number 2,

R^4 represents 2-hydroxyeth-1-yl or 4-hydroxycyclohex-1-yl,

R^5 represents hydrogen,

or one of its salts.

6. A compound according to Claim 1, wherein

R^1 represents methyl,

R^2 represents hydrogen,


or

R^1 represents methyl,

R^2 represents methyl,

and

R^3 represents a group of the formula



,

where

* is the point of attachment to the oxopyridine ring,

m represents the number 1,


R^6 represents 2-hydroxyeth-1-yl or 4-hydroxycyclohex-1-yl,

R^7 represents hydrogen,

or one of its salts.

7. A process for preparing a compound of the formula (I) or one or its salts according to Claim 1, comprising:

[A] reacting a compound of the formula




(II),

in which n, R^1 and R^2 have the meaning given in Claim 1, and

X represents hydroxyl or bromine,


with a compound of the formula



(III)

in which R^4 and R^5 have the meaning given in Claim 1,

to give a compound of the formula




(Ia)

in which n, R^1, R^2, R^4 and R^5 have the meaning given in Claim 1,

or

[B] reacting a compound of the formula




(IV)

in which m, R^1 and R^2 have the meaning given in Claim 1, and

Y represents hydroxyl or chlorine,


with a compound of the formula



(V)

in which R^6 and R^7 have the meaning given in Claim 1,

to give a compound of the formula



(Ib)

in which m, R^1, R^2, R^6 and R^7 have the meaning given in Claim 1.

8. A pharmaceutical composition comprising a compound according to Claim 1 and an inert nontoxic pharmaceutically acceptable auxiliary.

9. A pharmaceutical composition comprising a compound according to Claim 1 in combination with a further active compound.

10. A method for preventing blood coagulation in vitro, wherein an anticoagulatory effective amount of a compound according to Claim 1 is added.